Cytyc Gains Preterm Birth Diagnostic, Drug In $356 Mil. Adeza Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Cytyc is banking on its established women's health sales force to maximize the value of its $356 million purchase of Adeza Biomedical and its principal product Full Term, a diagnostic for preterm birth risk
You may also be interested in...
Cytyc’s Purchase Of Adiana Opens Door To Female Contraception Market
Cytyc could gain PMA approval by year-end for its newly acquired, non-incisional alternative to tubal ligation for permanent female contraception, according to the company
Cytyc’s Purchase Of Adiana Opens Door To Female Contraception Market
Cytyc could gain PMA approval by year-end for its newly acquired, non-incisional alternative to tubal ligation for permanent female contraception, according to the company
Danaher Beats Out Cytyc, Ventana In Battle For Vision Systems
Cytyc and Ventana are bowing out of a bidding war for cancer and infectious disease detection equipment maker Vision Systems, which says it prefers a richer offer valued at $520 mil. from diversified industrial firm Danaher